Por favor, use este identificador para citar o enlazar este ítem:
https://hdl.handle.net/10495/21555
Registro completo de metadatos
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.contributor.author | González Pérez, Javier Mauricio | - |
dc.contributor.author | Rodríguez Jaramillo, Carlos Andrés | - |
dc.contributor.author | Agudelo Pérez, María | - |
dc.contributor.author | Zuluaga Salazar, Andrés Felipe | - |
dc.contributor.author | Vesga Meneses, Omar | - |
dc.date.accessioned | 2021-08-06T11:33:44Z | - |
dc.date.available | 2021-08-06T11:33:44Z | - |
dc.date.issued | 2017 | - |
dc.identifier.issn | 1413-8670 | - |
dc.identifier.uri | http://hdl.handle.net/10495/21555 | - |
dc.description.abstract | ABSTRACT: The current increment of invasive fungal infections and the availability of new broad- spectrum antifungal agents has increased the use of these agents by non-expert practitioners, without an impact on mortality. To improve efficacy while minimizing prescription errors and to reduce the high monetary cost to the health systems, the principles of pharmacokinetics (PK) and pharmacodynamics (PD) are necessary. A systematic review of the PD of antifungals agents was performed aiming at the practicing physician without expertise in this field. The initial section of this review focuses on the general concepts of antimicrobial PD. In vitro studies, fungal susceptibility and antifungal serum concentrations are related with different doses and dosing schedules, determining the PD indices and the magnitude required to obtain a specific outcome. Herein the PD of the most used antifungal drug classes in Latin America (polyenes, azoles, and echinocandins) is discussed. | spa |
dc.format.extent | 9 | spa |
dc.format.mimetype | application/pdf | spa |
dc.language.iso | eng | spa |
dc.publisher | Brazilian Society of Infectious Diseases | spa |
dc.type.hasversion | info:eu-repo/semantics/publishedVersion | spa |
dc.rights | info:eu-repo/semantics/openAccess | spa |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/2.5/co/ | * |
dc.title | Antifungal pharmacodynamics : Latin America’s perspective | spa |
dc.type | info:eu-repo/semantics/article | spa |
dc.publisher.group | GRIPE: Grupo Investigador de Problemas en Enfermedades Infecciosas | spa |
dc.identifier.doi | 10.1016/j.bjid.2016.09.009 | - |
oaire.version | http://purl.org/coar/version/c_970fb48d4fbd8a85 | spa |
dc.rights.accessrights | http://purl.org/coar/access_right/c_abf2 | spa |
dc.identifier.eissn | 1678-4391 | - |
oaire.citationtitle | The Brazilian Journal of Infectious Diseases | spa |
oaire.citationstartpage | 79 | spa |
oaire.citationendpage | 87 | spa |
oaire.citationvolume | 21 | spa |
oaire.citationissue | 1 | spa |
dc.rights.creativecommons | https://creativecommons.org/licenses/by-nc-nd/4.0/ | spa |
dc.publisher.place | Salvador, Brasil | spa |
dc.type.coar | http://purl.org/coar/resource_type/c_dcae04bc | spa |
dc.type.redcol | https://purl.org/redcol/resource_type/ARTREV | spa |
dc.type.local | Artículo de revisión | spa |
dc.subject.decs | Antifúngicos | - |
dc.subject.decs | Antifungal Agents | - |
dc.subject.decs | Farmacología | - |
dc.subject.decs | Pharmacology | - |
dc.subject.decs | Farmacocinética | - |
dc.subject.decs | Pharmacokinetics | - |
dc.subject.decs | Candidiasis | - |
dc.subject.decs | Aspergilosis | - |
dc.subject.decs | Aspergillosis | - |
dc.description.researchgroupid | COL0005744 | spa |
dc.relation.ispartofjournalabbrev | Braz. J. Infect. Dis. | spa |
Aparece en las colecciones: | Artículos de Revista en Ciencias Médicas |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
JavierGonzales_2017_AntifungalPharmacodynamicsLatinAmerica.pdf | Artículo de revisión | 1.18 MB | Adobe PDF | Visualizar/Abrir |
Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons